Role of elevated cancer antigen 19-9 in women with mature cystic teratoma

Marina Frimer, Brandon Luke L Seagle, Scott Chudnoff, Gary L. Goldberg, Shohreh Shahabi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The objective of this study was to determine how often an elevated cancer antigen (CA) 19-9 (≥ 37 U/mL) was present during the preoperative evaluation of women with a mature cystic teratoma (MCT). This was a retrospective, consecutive case series (N = 139) of histologically proven MCT treated at Montefiore Medical Center from 1997 to 2008. Data were analyzed for patient and tumor characteristics, tumor markers (CA 19-9, CA 125, and carcinoembryonic antigen [CEA]), preoperative imaging, and procedure. CA 19-9 was elevated in 37.4% of patients. Elevated CA 19-9 was not significantly associated with age, race, CA 125 (≥35 U/mL), CEA (≥5 ng/mL), MCT size, or the presence of bilateral MCTs. Of the patients, 59% were ≥40 years old. Age <40 years was associated with cystectomy rather than oophorectomy (P <.001), regardless of CA 19-9 (P =.09). Elevated preoperative CA 19-9 in patients with MCT was associated with increased preoperative computed tomography (P =.04).

Original languageEnglish (US)
Pages (from-to)1307-1311
Number of pages5
JournalReproductive Sciences
Issue number10
StatePublished - Oct 11 2014


  • CA 19-9
  • adnexal mass
  • ovarian tumor
  • teratoma
  • tumor marker

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Role of elevated cancer antigen 19-9 in women with mature cystic teratoma'. Together they form a unique fingerprint.

Cite this